Managing Preserved and Reduced Ejection Fraction in Heart Failure: An Evidence-Based Case Review

Managing Preserved and Reduced Ejection Fraction in Heart Failure: An Evidence-Based Case Review

Faculty Presenters

Ty J. Gluckman, MD
Medical Director, Center for Cardiovascular Analytics, Research and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health
Portland, Oregon

Toby C. Trujillo, PharmD, FCCP, FAHA, BCPS-AQ Cardiology
Associate Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Clinical Specialist – Anticoagulation/Cardiology
Co-chair, Anticoagulation Subcommittee UC Health
University of Colorado Hospital
Aurora, Colorado
 
Program Description
Heart failure (HF) is a complex public health problem, with long-term management strategies focusing on preventing hospitalization, providing symptom relief, and improving patient quality of life. Clinical guidelines classify patients with HF as either with reduced ejection fraction or preserved ejection fraction (HFrEF, HFpEF). Guidelines further suggest considering specific pharmacologic therapies based on distinct patient risk factors and comorbidities, which the entire multidisciplinary team should recognize for hospitalized and outpatient individuals with HF. The presence of comorbidities in patients with HF can complicate medication management and, as central members of a patient’s care team, pharmacists must be prepared to adjust doses and modify high pill burden regimens for patients with HF.

Target audience: Health-system pharmacists
Type of activity: Application
Release date: December 16, 2020
Expiration date: December 16, 2021
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine current recommendations for guideline-directed medical therapy (GDMT), common comorbidities, and targeted therapies for the treatment of HFrEF, including emerging therapy options
• Identify current treatment and management of HFpEF and challenges faced in HFpEF treatment
• Explore clinical trial data of emerging therapies in the management of HFpEF

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-385-H01-P. The activity is available for CE credit through December 16, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty
Ty J. Gluckman, MD, and Toby C. Trujillo, PharmD, FCCP, FAHA, BCPS-AQ Cardiology, have no relevant financial relationships with commercial interests to disclose.

Medical Reviewer
Tien Ng, PharmD, FHFSA, FACC, FCCP, BCPS-AQ Cardiology, has the following relevant financial relationship with a commercial interest to disclose:

• Advisory Board: Alnylam Pharmaceuticals

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms